market_report

6.1 Market

Slide 1 - Cover (LAVisions layout)layout: title_hero · 16:9
Tola
Market Opportunity
Where we win, and why.
MK 01 / 10
Market opportunity
US clinical skincare, the fastest-growing slice of premium beauty, is briefing vendors for a new active
TAMSAMSOM
$4.8BTotal Addressable Market
US clinical skincare segment, 2025, growing 14% a year inside a $19.2B premium market
Prestige clinical buyers trading up from mass-clinical and reformulation launches.
$1.6BServiceable Addressable Market
$4.8B clinical segment filtered to Sephora, US specialty, and DTC premium-clinical buyers
Prestige clinical buyers reachable through Sephora and specialty over 24 to 36 months.
$13.75MServiceable Obtainable Market
Modelled cumulative revenue capture by 2030, about 0.17% of the clinical segment
Small share by design, defended by clinical proof and cooperative sourcing.
MK 02 / 10
Why now
Demand, supply, and retail are pointing at the same gap.
01
Consumer search is moving
US clinical-skincare search demand grew 71% year over year in 2023 to 2024. African-ingredient searches grew 134% off a smaller base.
02
Retailers are briefing for it
Sephora ran three buyer meetings across 2024 and 2025 asking vendors for a new active with clinical proof.
03
The clinical slice is compounding
The clinical segment of US premium skincare is growing 14% per year, ahead of the 8% category rate.
MK 03 / 10
Business model
Sephora acquires, tola.co retains
Main income
Four hero products from $42 to $94, plus two bundles
Wholesale to Sephora for reach, direct on tola.co at roughly double the contribution margin.
Unit economics
Unit Economics
$358 twenty-month customer value against $87 customer acquisition cost, a 4.0x ratio.
MK 04 / 10
Total Addressable Market
Top-down by market segment Total addressable market = US premium skincare x clinical share x current-year size Segment-by-segment across the US premium skincare market unit a = segment size in 2025; unit b = annual growth rate; unit c = clinical share of the segment
$4.8B
Prestige clinical skincare, the treatment-active core Segment size 2025 $4.8B Annual growth 14% Clinical share 100% $4.8B
Broader US premium skincare, the trade-up pool Segment size 2025 $19.2B Annual growth 8.1% Clinical share 25% $4.8B
US specialty and DTC premium-clinical retail Segment size 2025 $1.6B Annual growth 12% Clinical share 100% $1.6B
8.1% Compound Annual Growth Rate (2025 to 2029), source: Circana Beauty Brief, US premium skincare from $19.2B to $26.1B Top-down, Circana Beauty Brief 2025
MK 05 / 10
Serviceable Addressable Market $1.6B

Filters applied to TAM:

Channel fit: Sephora, US specialty, and DTC premium-clinical only - 60% concentrates the clinical segment on the channels TOLA is contracted or launching into
Price tier: mid-prestige $42 to $94 buyers - 80% excludes the mass-clinical and ultra-prestige tiers outside TOLA's price band
Buyer readiness: trading up to clinical proof - 85% excludes buyers still anchored to commodity actives with no interest in published efficacy
Reach window: reachable through contracted retail in 24 to 36 months - 82% excludes regions and doors outside the contracted Sephora and international launch schedule
$4.8B x 60% x 80% x 85% x 82% = $1.6B Serviceable Addressable Market
TAM
× 90%
× 89%
× 99%
× 99%
SAM
MK 06 / 10
Serviceable Obtainable Market Our target in 5 years $13.75M
Year tam unit a label tam unit b label tam unit c label Total
Y1 y1 unit a count y1 unit b rate y1 unit c value y1 total
Y2 y2 unit a count y2 unit b rate y2 unit c value y2 total
Y3 y3 unit a count y3 unit b rate y3 unit c value y3 total
Y4 y4 unit a count y4 unit b rate y4 unit c value y4 total
Y5 y5 unit a count y5 unit b rate y5 unit c value y5 total
Active users01M2M3M4M150K600K1.4M2.6M3.8MYear 1Year 2Year 3Year 4Year 5
MK 07 / 10
Industry Growth and CAGR8.1% premium growth, 14% in the clinical slice, through 2029
1×2×3×1.0×3.3×27% CAGR202520262027202820292030Circana and Statista, 2025
US premium skincare $19.2B in 2025 to $26.1B by 2029 | https://www.circana.com/
US clinical skincare segment $4.8B in 2025, growing 14% a year | https://www.circana.com/
Clinical-skincare Google search +71% year over year 2023 to 2024 | https://www.statista.com/
African plant ingredient search +134% off a smaller base 2023 to 2024 | https://www.statista.com/
MK 08 / 10
Market Challenges Four real risks, and each one is also an opening for TOLA
Incumbents copy the clinical claim A determined competitor can replicate an IRB study in 18 to 24 months Win the shelf first, bank the sell-through data, and lock cooperative supply
Sephora sell-through has to hold at scale The 450-door rollout must repeat the 89% pilot sell-through Front-of-aisle display, contracted door count, per-door productivity from the pilot
Ingredient supply is agricultural Botanical actives depend on growing seasons and cooperative capacity Multi-year contracts at 28% above commodity, four cooperatives by Q2 2026
Category crowds and CAC rises Customer acquisition cost climbs from $87 as clinical brands multiply Subscription launch, bundle attach, and the online retention margin defend LTV
MK 09 / 10
Key Takeaway Clinical skincare, proven, priced, and defensible
Total Addressable Market $4.8B
Serviceable Addressable Market $1.6B
Serviceable Obtainable Market $13.75M
Compound Annual Growth Rate 14.0%
MK 10 / 10